| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.14 | 0.006 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.006 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.16 | 0.007 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.008 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.093 | 0.008 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.081 | 0.008 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.13 | 0.008 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.096 | 0.008 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.098 | 0.009 |